[3H]MK-801 binding in Alzheimer's disease. 1988

M M Mouradian, and P C Contreras, and J B Monahan, and T N Chase
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20892.

The density of [3H]MK-801 binding sites was studied in homogenates prepared from different cortical regions of postmortem brains of Alzheimer patients and age matched controls. Highest number of binding sites for this noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor was in temporal pole (Brodmann area A-38) in both groups. There were no consistent differences between patients and controls in either binding density or affinity constant in any of the areas studied. Involvement of glutamatergic neurotransmission in Alzheimer's disease does not seem to be at the level of the MK-801 recognition site on the NMDA receptor complex.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D003986 Dibenzocycloheptenes A family of tricyclic hydrocarbons whose members include many of the commonly used tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC).
D005260 Female Females
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia

Related Publications

M M Mouradian, and P C Contreras, and J B Monahan, and T N Chase
September 1989, Journal of neurochemistry,
M M Mouradian, and P C Contreras, and J B Monahan, and T N Chase
April 1990, Journal of neurochemistry,
M M Mouradian, and P C Contreras, and J B Monahan, and T N Chase
May 1989, Brain research,
M M Mouradian, and P C Contreras, and J B Monahan, and T N Chase
December 1991, Neuroscience letters,
M M Mouradian, and P C Contreras, and J B Monahan, and T N Chase
October 1993, Brain research,
M M Mouradian, and P C Contreras, and J B Monahan, and T N Chase
January 1989, Acta neurologica Belgica,
M M Mouradian, and P C Contreras, and J B Monahan, and T N Chase
March 1989, European journal of pharmacology,
M M Mouradian, and P C Contreras, and J B Monahan, and T N Chase
April 1988, British journal of pharmacology,
M M Mouradian, and P C Contreras, and J B Monahan, and T N Chase
November 1991, Brain research,
M M Mouradian, and P C Contreras, and J B Monahan, and T N Chase
June 1994, Neuroreport,
Copied contents to your clipboard!